Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

Pfizer will publish full proposals of funded initiatives, in addition to any milestone updates, interim reports, final outcomes assessments and any other relevant, pertinent data and information that ...

Pfizer Digital continuously seeks opportunities to bring fresh and innovative ideas to our business. The Digital Rotational Program is looking for recent college graduates to join our fast-paced ...

Technology moves fast, and there’s no better example than the rapid growth of artificial intelligence (AI). Here at Pfizer, we have long been focused on making breakthroughs that change patients’ ...

The Pfizer Futures assessment is designed to help us better understand your potential and identify candidates who may thrive within Pfizer's values-driven culture and future talent pipeline As part of ...

TOKYO & Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved a ...

Financial guidance for Adjusted (2) diluted EPS is calculated using approximately 5.74 billion weighted average shares outstanding, and assumes no share repurchases in 2024 or 2025.

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...

COMIRNATY is the first COVID-19 vaccine to be granted FDA approval Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose More than 1.2 ...

U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately Pfizer and BioNTech previously announced an agreement with the U.S.

NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...